Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 7:8:647582.
doi: 10.3389/fnut.2021.647582. eCollection 2021.

Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review

Affiliations
Review

Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review

Sami A Al-Harbi et al. Front Nutr. .

Abstract

Cancer as a disease continues to ravage the world population without regard to sex, age, and race. Due to the growing number of cases worldwide, cancer exerts a significant negative impact on global health and the economy. Interestingly, chemotherapy has been used over the years as a therapeutic intervention against cancer. However, high cost, resistance, and toxic by-effects to treatment have overshadowed some of its benefits. In recent times, efforts have been ongoing in searching for anticancer therapeutics of plant origin, focusing on polyphenols. Urolithins are secondary polyphenol metabolites derived from the gut microbial action on ellagitannins and ellagic acid-rich foods such as pomegranate, berries, and nuts. Urolithins are emerging as a new class of anticancer compounds that can mediate their cancer-preventive activities through cell cycle arrest, aromatase inhibition, induction of apoptosis, tumor suppression, promotion of autophagy, and senescence, transcriptional regulation of oncogenes, and growth factor receptors. In this review, we discussed the growing shreds of evidence supporting these secondary phenolic metabolites' anticancer properties. Furthermore, we have pointed out some of the future directions needed to establish urolithins as anticancer agents.

Keywords: anticancer; ellagitannins; metabolites; polyphenols; urolithins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
A summarized pathway for the formation of urolithins from ellagitannin and ellagic acid in the gut. Following the ingestion of food containing ellagitannins, they are hydrolyzed in the stomach to yield ellagic acid. The ellagic acid then undergoes series of transformations by the gut microbiota forming different urolithin molecules. Created with ChemSketch and BioRender.com.
Figure 2
Figure 2
A summary of pathways targeted by urolithins in mediating their anticancer activity. The urolithins mechanism of action involves decreased oxidative stress, cell cycle arrest, inhibition of survival pathways, induction of apoptosis, tumor suppression, promotion of autophagy and senescence, transcriptional regulation of oncogenes, inhibition of growth factor receptors, and upregulation of tumor suppressor genes.

References

    1. Kim EK, Choi EJ, Debnath T. Role of phytochemicals in the inhibition of epithelial-mesenchymal transition in cancer metastasis. Food Funct. (2016) 7:3677–85. 10.1039/c6fo00901h - DOI - PubMed
    1. Oyenihi A, Smith C. Are polyphenol antioxidants at the root of medicinal plant anti-cancer success? J Ethnopharmacol. (2018) 229:54–72. 10.1016/j.jep.2018.09.037 - DOI - PubMed
    1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. (2016) 25:16–27. 10.1158/1055-9965.Epi-15-0578 - DOI - PubMed
    1. Hasan MN, Razvi SSI, Kuerban A, Balamash KS, Al-Bishri WM, Abulnaja KO, et al. . Strigolactones-a novel class of phytohormones as anti-cancer agents. J Pestic Sci. (2018) 43:168–72. 10.1584/jpestics.D17-090 - DOI - PMC - PubMed
    1. IARC . Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018. Lodz: The International Agency for Research on Cancer (IARC) (2018).

LinkOut - more resources